PCVX on Nasdaq
Vaxcyte, Inc.
In its 2026 annual report the company says: “We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF™ cell-free protein synthesis platform.”4 It is headquartered in San Carlos, United States.2 Its shares trade on Nasdaq under the symbol PCVX.2
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerPCVX on Nasdaq2
- IndustryBiological Products, (No Diagnostic Substances)2
- HeadquartersSan Carlos, United States2
- Incorporated inDE3
- Business address825 Industrial Road, Ste. 300, San Carlos, Ca 940703
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- LEI254900M7NMHTGASX8D952
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 54408502
See how the biggest companies compare on our leaderboards
We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF™ cell-free protein synthesis platform. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that are beyond the capabilities of conventional approaches.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $794.3M | $476.6M | $332.3M |
| Acquired manufacturing rights | $0 | $0 | $75.0M |
| General and administrative | $129.4M | $92.9M | $60.7M |
| Total operating expenses | $923.7M | $569.5M | $468.0M |
| Loss from operations | -$923.7M | -$569.5M | -$468.0M |
| Interest income | $119.7M | $110.0M | $62.9M |
| Other income (expense) | $37.3M | -$4.4M | $2.9M |
| Total other income, net | $157.0M | $105.6M | $65.8M |
| Net loss | -$766.6M | -$463.9M | -$402.3M |
| Net loss per share, basic (in dollars per share) | -$5.63 | -$3.80 | -$4.14 |
| Net loss per share, diluted (in dollars per share) | -$5.63 | -$3.80 | -$4.14 |
| Weighted-average shares outstanding, basic (in shares) | 136.1M shares | 122.0M shares | 97.2M shares |
| Weighted-average shares outstanding, diluted (in shares) | 136.1M shares | 122.0M shares | 97.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $174.0M | $387.9M | $397.5M | |
| Short-term investments | $1.4B | $1.4B | ||
| Prepaid expenses and other current assets | $66.4M | $40.8M | ||
| Total current assets | $1.6B | $1.8B | ||
| Property and equipment, net | $257.4M | $198.0M | ||
| Operating lease right-of-use assets | $116.0M | $72.1M | ||
| Long-term investments | $881.7M | $1.4B | ||
| Restricted cash | $1.5M | $1.3M | ||
| Other assets | $118.8M | $64.4M | ||
| Total noncurrent assets | $1.4B | $1.7B | ||
| Total assets | $3.0B | $3.5B | ||
| Accounts payable | $70.9M | $48.5M | ||
| Accrued compensation | $23.0M | $20.6M | ||
| Accrued contract manufacturing expenses | $74.7M | $36.2M | ||
| Accrued expenses | $31.1M | $29.1M | ||
| Operating lease liabilities current | $6.1M | $5.9M | ||
| Total current liabilities | $205.8M | $140.2M | ||
| Operating lease liabilities long-term | $111.4M | $65.2M | ||
| Other liabilities | $100.0K | $100.0K | ||
| Total liabilities | $317.2M | $205.5M | ||
| Preferred stock, $0.001 par value 10,000,000 authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 131,058,858 and 124,893,034 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $134.0K | $128.0K | ||
| Additional paid-in capital | $4.8B | $4.7B | ||
| Accumulated other comprehensive income (loss) | $1.6M | -$3.9M | ||
| Accumulated deficit | -$2.2B | -$1.4B | ||
| Total stockholders' equity | $2.7B | $3.3B | $1.2B | $953.6M |
| Total liabilities and stockholders' equity | $3.0B | $3.5B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 131.1M shares | 124.9M shares | ||
| Common stock, shares outstanding (in shares) | 131.1M shares | 124.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $174.0M | $387.9M | $397.5M | |
| Short-term investments | $1.4B | $1.4B | ||
| Prepaid expenses and other current assets | $66.4M | $40.8M | ||
| Total current assets | $1.6B | $1.8B | ||
| Property and equipment, net | $257.4M | $198.0M | ||
| Operating lease right-of-use assets | $116.0M | $72.1M | ||
| Long-term investments | $881.7M | $1.4B | ||
| Restricted cash | $1.5M | $1.3M | ||
| Other assets | $118.8M | $64.4M | ||
| Total noncurrent assets | $1.4B | $1.7B | ||
| Total assets | $3.0B | $3.5B | ||
| Accounts payable | $70.9M | $48.5M | ||
| Accrued compensation | $23.0M | $20.6M | ||
| Accrued contract manufacturing expenses | $74.7M | $36.2M | ||
| Accrued expenses | $31.1M | $29.1M | ||
| Operating lease liabilities current | $6.1M | $5.9M | ||
| Total current liabilities | $205.8M | $140.2M | ||
| Operating lease liabilities long-term | $111.4M | $65.2M | ||
| Other liabilities | $100.0K | $100.0K | ||
| Total liabilities | $317.2M | $205.5M | ||
| Preferred stock, $0.001 par value 10,000,000 authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 131,058,858 and 124,893,034 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $134.0K | $128.0K | ||
| Additional paid-in capital | $4.8B | $4.7B | ||
| Accumulated other comprehensive income (loss) | $1.6M | -$3.9M | ||
| Accumulated deficit | -$2.2B | -$1.4B | ||
| Total stockholders' equity | $2.7B | $3.3B | $1.2B | $953.6M |
| Total liabilities and stockholders' equity | $3.0B | $3.5B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 131.1M shares | 124.9M shares | ||
| Common stock, shares outstanding (in shares) | 131.1M shares | 124.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$766.6M | -$463.9M | -$402.3M |
| Depreciation and amortization | $16.4M | $7.0M | $3.2M |
| Stock-based compensation expense | $138.8M | $84.8M | $48.8M |
| Amortization of operating lease right-of-use assets | $8.5M | $8.8M | $7.0M |
| Net accretion of discounts on investments | -$14.4M | -$38.7M | -$34.8M |
| Unrealized foreign exchange loss (gain) | -$34.8M | $4.2M | $0 |
| Prepaid expenses and other current assets | -$16.8M | -$5.8M | $17.9M |
| Operating lease right-of-use assets | -$52.4M | -$49.9M | -$16.7M |
| Other assets | -$39.9M | -$26.5M | -$33.0M |
| Operating lease liabilities | $46.4M | $41.9M | $11.3M |
| Accounts payable | $19.9M | $34.6M | $11.2M |
| Accrued compensation | $2.3M | $9.5M | $9.9M |
| Accrued contract manufacturing expenses | $31.1M | -$22.9M | $44.5M |
| Accrued expenses | $6.0M | -$35.7M | $36.3M |
| Net cash used in operating activities | -$655.6M | -$452.6M | -$296.8M |
| Purchases of property and equipment | -$13.7M | -$22.4M | -$16.1M |
| Purchases of manufacturing facility build-out and equipment construction-in-progress | -$43.3M | -$96.7M | -$51.8M |
| Purchases of investments | $1.2B | $3.1B | $1.3B |
| Maturities of investments | $1.5B | $1.1B | $611.9M |
| Sales of investments | $174.7M | $67.0M | $12.6M |
| Net cash provided by (used in) investing activities | $437.4M | -$2.0B | -$773.3M |
| Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs | $0 | $2.2B | $545.3M |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs | $0 | $195.9M | $90.7M |
| Proceeds from issuance of shares through employee equity incentive plans | $13.0M | $27.1M | $7.6M |
| Taxes paid related to the net share settlement of equity awards | -$11.0M | -$14.3M | -$3.9M |
| Net cash provided by financing activities | $2.0M | $2.4B | $639.8M |
| Effect of exchange rate changes on cash and cash equivalents | $2.4M | $426.0K | -$6.7M |
| Net decrease in cash, cash equivalents and restricted cash | -$213.8M | -$9.4M | -$437.0M |
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $7.5M | $13.2M | $8.5M |
No quarter-by-quarter statement was filed.
Corporate structure
Vaxcyte, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Vaxcyte, Inc.
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Vaxcyte, Inc., latest Aug 11, 2026 (11 filings since Feb 10, 2022)
- FMR LLC Filed SCHEDULE 13G/A on Vaxcyte, Inc., latest Aug 6, 2026 (9 filings since Feb 9, 2022)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on Vaxcyte, Inc., latest May 15, 2026 (5 filings since Feb 14, 2023)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Vaxcyte, Inc., latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Vaxcyte, Inc., latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- T. Rowe Price Investment Management, Inc. Filed SCHEDULE 13G/A on Vaxcyte, Inc., latest Feb 17, 2026 (2 filings since Nov 14, 2025)
- BlackRock Filed SCHEDULE 13G/A on Vaxcyte, Inc., latest Apr 17, 2025 (5 filings since Feb 4, 2022)
- Carlyle Group Filed SC 13G/A on Vaxcyte, Inc., latest Feb 10, 2023
- TPG GP A, LLC Filed SC 13G/A on Vaxcyte, Inc., latest Feb 10, 2023 (2 filings since Jan 18, 2022)
- Longitude Venture Partners II, L.P. Filed SC 13G/A on Vaxcyte, Inc., latest Feb 15, 2022
- Abingworth LLP Filed SC 13G/A on Vaxcyte, Inc., latest Feb 14, 2022
- ROCHE FINANCE LTD Filed SC 13G/A on Vaxcyte, Inc., latest Feb 14, 2022
- Vaxcyte, Inc. San Carlos, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Vaxcyte, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $290.1M9 Dec 31, 2025 | $214.3M9 Dec 31, 2024 | +35.4% |
| Accumulated depreciation | $32.8M9 Dec 31, 2025 | $16.3M9 Dec 31, 2024 | +101.4% |
| Property and equipment, net | $257.4M9 Dec 31, 2025 | $198.0M9 Dec 31, 2024 | +30.0% |
| Operating-lease assets (leased space) | $116.0M9 Dec 31, 2025 | $72.1M9 Dec 31, 2024 | +60.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $174.0M9 Dec 31, 2025 | $387.9M9 Dec 31, 2024 | −55.2% |
| Marketable securities, current | $1.4B9 Dec 31, 2025 | $1.4B9 Dec 31, 2024 | +2.0% |
| Debt securities available for sale | $2.3B9 Dec 31, 2025 | $2.7B8 Dec 31, 2024 | −17.4% |
| Long-term investments | $881.7M9 Dec 31, 2025 | $1.4B9 Dec 31, 2024 | −36.5% |
Properties, in its own words
Our corporate headquarters is located in San Carlos, California, where we currently lease and occupy 195,633 square feet of laboratory and office space pursuant to an Amended and Restated Lease Agreement (the “Amended and Restated Lease”). Our Amended and Restated Lease premises consist of an aggregate of approximately 258,581 square feet of laboratory and office space, of which (i) 16,731 square feet we currently sublet, and (ii) 46,217 square feet of which the lease commencements will begin starting in 2026. Our Amended and Restated Lease expires on February 28, 2035. We use our corporate headquarters primarily for corporate research, development, regulatory, manufacturing and quality functions. We believe that our existing facilities are adequate to meet our current needs.
Item 2 of the 10-K filed Feb 24, 2026.4
Leadership
Who has led Vaxcyte, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerGrant Pickering Jun 11, 2020 to now13
- PresidentAndrew Guggenhime Apr 6, 2021 to now14
- PresidentGrant Pickering Jun 11, 2020 to Mar 23, 202113
- Chief financial officerAndrew Guggenhime Jun 11, 2020 to now15
- Chief operating officerJim Wassil Jun 11, 2020 to now16
Board members and other officers (22)
- Chief Medical OfficerLuis Jodar Sep 9, 2026 to now17
- OfficerElvia Cowan Jan 4, 2023 to now18
- SVP, Gen Counsel & Corp SecMikhail Eydelman Apr 11, 2022 to Mar 7, 202519
- SVP Cml Mfg & Supply ChainHarpreet S. Dhaliwal Oct 6, 2021 to now20
- VP, ResearchJeff Fairman Jun 11, 2020 to Jan 4, 202321
- SVP Process Dev, ManufacturingPaul Sauer Jun 11, 2020 to Jan 4, 202322
- Board memberJohn Markels Jul 16, 2026 to now23
- Board memberJacks Lee Nov 29, 2023 to now24
- Board memberTeri Loxam Sep 20, 2021 to now25
- Board memberAnne S. Drapeau Sep 24, 2021 to now26
- Board memberCarlos Paya V. Oct 29, 2021 to now27
- Board memberMichael E. Kamarck Oct 29, 2021 to Jun 15, 202328
- Board memberGrant Pickering Jun 11, 2020 to now13
- Board memberHalley E. Gilbert Jun 11, 2020 to now29
- Board memberHeath Lukatch Jun 11, 2020 to now30
- Board memberKurt Von Emster Jun 11, 2020 to Jun 3, 202131
- Board memberMoncef Slaoui Jun 11, 2020 to now32
- Board memberPatrick J. Heron Jun 11, 2020 to Jun 3, 202133
- Board memberPeter Hirth Jun 11, 2020 to Jun 10, 202434
- Board memberRobert Lorne Hopfner Jun 11, 2020 to Jun 3, 202135
- Board memberWilliam J. Newell Jun 11, 2020 to Dec 10, 202036
- General counselJane Wright Mitchell Jun 11, 2020 to Aug 18, 202137
Former names
- SutroVax, Inc.Jul 24, 2015 to Apr 3, 20203
Timeline
- Oct 9, 20268-K Entered a material agreement; New debt or obligation; Other events38
- Oct 5, 20268-K Regulation FD disclosure; Other events39
- Sep 3, 20268-K Executive or director change; Regulation FD disclosure40
- Aug 5, 20268-K Results of operations41
- Jul 15, 20268-K Executive or director change42
- Jun 23, 20268-K Executive or director change43
- Jun 16, 20268-K Shareholder vote44
- May 6, 20268-K Results of operations45
- Feb 24, 20268-K Results of operations46
- Feb 24, 20268-K Other events47
- Feb 2, 20268-K Other events48
- Dec 19, 20258-K Executive or director change49
- Jun 11, 2020New chief executive Grant Pickering becomes CEO13
- Nov 27, 2013Founded Vaxcyte, Inc. is founded2
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.56) a share, on Nov 4, 2025.50
When it reported results
- Aug 5, 2026Reported quarterly or annual results41
- May 6, 2026Reported quarterly or annual results45
- Feb 24, 2026Reported quarterly or annual results46
- Nov 4, 2025Reported quarterly or annual results51
- Aug 6, 2025Reported quarterly or annual results52
- May 7, 2025Reported quarterly or annual results53
- Feb 25, 2025Reported quarterly or annual results54
- Nov 5, 2024Reported quarterly or annual results55
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
614 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 325 insider forms, 43 large holders, 169 other. The latest 20:
- Oct 9, 20268-K EDGAR
- Oct 8, 2026424B5 EDGAR
- Oct 8, 2026424B5 EDGAR
- Oct 7, 20264 EDGAR
- Oct 7, 20264 EDGAR
- Oct 7, 2026FWP EDGAR
- Oct 6, 2026305B2 EDGAR
- Oct 6, 2026424B5 EDGAR
- Oct 6, 2026424B5 EDGAR
- Oct 5, 2026144 EDGAR
- Oct 5, 2026144 EDGAR
- Oct 5, 20268-K EDGAR
- Oct 2, 20264 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20263 EDGAR
- Sep 9, 2026144 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
The 614 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
181 open-market trades by officers, directors and large owners since October 2021: 0 buys and 181 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 1,334 | $59.52 | $79.4K | Form 4 |
| Sep 4, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 1,381 | $61.16 | $84.5K | Form 4 |
| Sep 1, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 3,477 | $61.08 | $212.4K | Form 4 |
| Aug 5, 2026 | Dhaliwal Harpreet S.Chief Technical Ops Officer | Sale | 17,000 | $55.00 | $935.0K | Form 4 |
| Aug 3, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 2,250 | $53.86 | $121.2K | Form 4 |
| Aug 3, 2026 | GUGGENHIME ANDREWPRESIDENT AND CFO | Sale | 10,000 | $53.89 | $538.9K | Form 4 |
| Jul 27, 2026 | PICKERING GRANTCHIEF EXECUTIVE OFFICER | Sale | 18,198 | $55.63 | $1.0M | Form 4 |
| Jul 6, 2026 | GUGGENHIME ANDREWPRESIDENT AND CFO | Sale | 10,000 | $57.29 | $572.9K | Form 4 |
| Jul 1, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 2,250 | $56.33 | $126.7K | Form 4 |
| Jun 26, 2026 | PICKERING GRANTCHIEF EXECUTIVE OFFICER | Sale | 24,237 | $55.22 | $1.3M | Form 4 |
| Jun 18, 2026 | PICKERING GRANTCHIEF EXECUTIVE OFFICER | Sale | 24,461 | $52.50 | $1.3M | Form 4 |
| Jun 18, 2026 | GUGGENHIME ANDREWPRESIDENT AND CFO | Sale | 10,000 | $53.00 | $530.0K | Form 4 |
| Jun 1, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 2,250 | $49.52 | $111.4K | Form 4 |
| May 1, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 2,250 | $56.83 | $127.9K | Form 4 |
| Apr 7, 2026 | Cowan ElviaSVP, Finance & CAO | Sale | 3,000 | $60.00 | $180.0K | Form 4 |
| Apr 1, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 2,250 | $58.43 | $131.5K | Form 4 |
| Mar 17, 2026 | Cowan ElviaSVP, Finance & CAO | Sale | 1,892 | $55.58 | $105.2K | Form 4 |
| Mar 11, 2026 | Cowan ElviaSVP, Finance & CAO | Sale | 2,500 | $58.59 | $146.5K | Form 4 |
| Mar 10, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Sale | 7,395 | $58.88 | $435.4K | Form 4 |
| Dec 31, 2025 | Dhaliwal Harpreet S.Chief Technical Ops Officer | Sale | 9,743 | $46.69 | $454.9K | Form 4 |
All 181 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 11 filings Feb 10, 2022 to Aug 11, 202656
- FMR LLCSCHEDULE 13G/A, 9 filings Feb 9, 2022 to Aug 6, 202657
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 5 filings Feb 14, 2023 to May 15, 202658
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202659
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202660
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A, 2 filings Nov 14, 2025 to Feb 17, 202661
- BlackRockSCHEDULE 13G/A, 5 filings Feb 4, 2022 to Apr 17, 202562
- Carlyle GroupSC 13G/A, 1 filing Feb 10, 202363
- TPG GP A, LLCSC 13G/A, 2 filings Jan 18, 2022 to Feb 10, 202364
- Longitude Venture Partners II, L.P.SC 13G/A, 1 filing Feb 15, 202265
- Abingworth LLPSC 13G/A, 1 filing Feb 14, 202266
- ROCHE FINANCE LTDSC 13G/A, 1 filing Feb 14, 202267
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Grant E. Pickering | 58 | $800.0K | $14.5M68 |
| 2025 | Andrew Guggenhime | 57 | $620.0K | $6.1M68 |
| 2025 | Jim Wassil | 56 | $600.0K | $5.8M68 |
| 2025 | Mikhail Eydelman | $501.0K | $4.0M68 | |
| 2025 | Harp Dhaliwal | 53 | $495.0K | $3.8M68 |
| 2024 | Chief Executive Officer | $700.0K | $39.6M68 | |
| 2024 | President and Chief Financial Officer | $556.0K | $17.9M68 | |
| 2024 | Executive VicePresident and Chief Operating Officer | $550.0K | $17.9M68 | |
| 2024 | Senior Vice PresidentGeneral Counsel and Corporate Secretary | $477.0K | $5.7M68 | |
| 2023 | Chief Executive Officer | $640.0K | $12.1M68 | |
| 2023 | President and Chief Financial Officer | $517.0K | $5.4M68 | |
| 2023 | Executive VicePresident and Chief Operating Officer | $508.0K | $5.4M68 | |
| 2023 | Senior Vice PresidentGeneral Counsel and Corporate Secretary | $448.1K | $3.5M68 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 20,852,907 | $1.2B | 0.1% | +4,360,046 |
| Jupiter Topco LLC | 17,965,847 | $1.0B | 0.4% | New |
| BlackRock, Inc. | 12,068,129 | $701.5M | 0.0% | +1,096,313 |
| Ra Capital Management, L.P. | 11,474,599 | $667.0M | 5.8% | No change |
| Wellington Management Group Llp | 7,001,565 | $407.0M | 0.1% | +1,386,968 |
| Vanguard Portfolio Management LLC | 6,593,551 | $383.3M | 0.0% | +314,006 |
| Vanguard Capital Management LLC | 6,348,679 | $369.0M | 0.0% | +81,978 |
| State Street Corp | 5,351,698 | $311.1M | 0.0% | +911,179 |
| Deep Track Capital, LP | 4,300,000 | $250.0M | 3.7% | No change |
| Geode Capital Management, LLC | 3,459,363 | $201.1M | 0.0% | +258,080 |
| Kynam Capital Management, LP | 2,922,335 | $169.9M | 9.4% | No change |
| Westfield Capital Management Co LP | 2,472,428 | $143.7M | 0.5% | −1,173,710 |
| Caligan Partners LP | 2,188,636 | $127.2M | 6.1% | +127,917 |
| Paradigm Biocapital Advisors LP | 2,127,852 | $123.7M | 2.3% | −2,665,168 |
| Bellevue Group AG | 1,971,935 | $114.6M | 2.4% | +781,238 |
| D. E. Shaw & Co., Inc. | 1,901,872 | $110.6M | 0.1% | −963,446 |
| Maverick Capital Ltd | 1,613,242 | $93.8M | 0.8% | +235,504 |
| Charles Schwab Investment Management Inc | 1,464,812 | $85.1M | 0.0% | +60,864 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,425,470 | $82.9M | 26.9% | +53,045 |
| Eventide Asset Management, LLC | 1,380,219 | $80.2M | 1.1% | +5,927 |
| Goldman Sachs Group Inc | 1,350,760 | $78.5M | 0.0% | +75,724 |
| Northern Trust Corp | 1,280,172 | $74.4M | 0.0% | +135,703 |
| Norges Bank | 1,245,805 | $72.4M | 0.0% | New |
| Jpmorgan Chase & Co | 1,227,346 | $71.2M | 0.0% | +219,032 |
| Dimensional Fund Advisors LP | 1,194,754 | $69.4M | 0.0% | +818,982 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jul 16, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +13.7% | Report |
| May 13, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +16.3% | Report |
| May 12, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +16.3% | Report |
| Apr 28, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +58.3% | Report |
| Apr 15, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +72.4% | Report |
| Apr 14, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +60.6% | Report |
| Mar 5, 2025 | Jefferson ShreveRepublican, House | Sale | $15,001 - $50,000 | +44.0% | Report |
| Dec 12, 2022 | Christopher L. Jacobs, House | Sale | $1,001 - $15,000 | +45.7% | Report |
| Nov 8, 2022 | Christopher L. Jacobs, House | Buy | $1,001 - $15,000 | −56.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Vaxcyte, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARVaxcyte, Inc.1
- CIK0001649094
- Employer ID (EIN)46-42333854
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address825 Industrial Road, Ste. 300, San Carlos, CA 940701
- Phone650-837-01111
- Shares outstanding148,805,278 as of Aug 3, 202611
- Public float$3.7B as of Jun 30, 20254
- AuditorDeloitte & Touche LLP, San Francisco, California PCAOB ID 34; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJul 24, 20151
- Filings761 in all: 4 (383), 144 (122), 8-K (68), 3 (32), SC 13G/A (25), 10-Q (19), 424B5 (18), SCHEDULE 13G/A (17)1
All 34 form types
SC 13G (10), S-8 (7), 10-K (6), DEF 14A (6), DEFA14A (6), UPLOAD (5), ARS (4), CORRESP (4), D (4), 4/A (3), S-3ASR (3), 144/A (2), DRS/A (2), DRSLTR (2), SCHEDULE 13G (2), 305B2 (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), FWP (1), PRE 14A (1), S-1 (1), S-1/A (1), S-1MEF (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 23, 2026
Latest 8-K (8-K) Oct 9, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value per share | PCVX | The Nasdaq Stock Market |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Vaxcyte, Inc. names in Item 1A of its 10-K filed Feb 24, 2026: 70 risks under these headings, as written.4
- Risks Related to Our Financial Position and Capital Needs
- We are in the clinical or preclinical stages of vaccine development and have a limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
- We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future. We currently have no source of product revenue and may never achieve profitability. Our stock is a highly speculative investment.
- We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.
- Due to the significant resources required for the development of our vaccine candidates, and depending on our ability to access capital, we must prioritize development of certain vaccine candidates. Moreover, we may expend our limited resources on vaccine candidates that do not yield a successful vaccine and fail to capitalize on vaccine candidates that may be more profitable or for which there is a greater likelihood of success.
- Risks Related to Our Business and Industry
- Our approach to the discovery and development of our vaccine candidates is based on novel technologies that are unproven, which may expose us to unforeseen risks, require us to modify processes, and make it difficult to predict the time and cost of vaccine candidate development and the timing to apply for and obtain regulatory approvals.
- Our vaccine candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of or commercialize our vaccine candidates or experience significant delays in doing so, our business would be materially harmed.
- Our business is highly dependent on the success of our PCV candidates. If we are unable to successfully develop, obtain approval for and effectively commercialize our PCV candidates, our business would be significantly harmed.
- Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop and commercialize our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us.
- We and our contract manufacturers may face difficulty satisfying CMC requirements imposed by the FDA and comparable foreign regulatory authorities. To date, no product developed using a cell-free manufacturing platform has received approval from the FDA or been commercialized.
- Even if we obtain regulatory approval of our vaccine candidates, the products may not gain market acceptance among regulators, advisory boards, physicians, patients, third-party payors and others in the medical community necessary for commercial success.
The other 60 risks
- We may not be successful in our efforts to use our cell-free protein synthesis platform to expand our pipeline of vaccine candidates and develop marketable products.
- Our vaccine candidates may cause undesirable side effects or have other properties, including interactions with existing vaccine regimens, that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
- Negative developments and negative public opinion of vaccines or new technologies on which we rely may damage public perception of our vaccine candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our vaccine candidates.
- We may not be able to file IND applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.
- We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.
- If we encounter difficulties enrolling subjects in any clinical trials we may conduct, including any field efficacy trials that may be required, our clinical development activities could be delayed or otherwise adversely affected.
- Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- We have in the past and may in the future seek breakthrough therapy designation ("BTD") or Fast Track designation by the FDA for one or more of our vaccine candidates, but we may not receive the designations we seek, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our vaccine candidates will receive marketing approval.
- We currently have no marketing and sales organization, and as an organization have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our vaccine candidates, we may not be able to generate product revenue.
- A variety of risks associated with our current and potential international operations and collaborations could materially adversely affect our business.
- We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain highly qualified personnel, we may not be able to successfully implement our business strategy.
- We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.
- Obtaining and maintaining regulatory approval of our vaccine candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our vaccine candidates in other jurisdictions.
- We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
- Revenue from any “catch up” opportunity may decline over time as more of the patient population is vaccinated.
- If our information technology systems or those of the third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, significant fines
- or other liability; regulatory investigations or actions; disruptions of our development programs or business operations; harms to our reputation; and other adverse consequences.
- Use of artificial intelligence in our operations could result in reputational or competitive harm and legal or regulatory liability.
- Natural or man-made disasters or business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our vaccine candidates.
- Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
- Changes in tax laws or tax rulings could affect our financial position.
- Our ability to utilize our net operating loss ("NOL") carryforwards and certain other tax attributes may be limited.
- Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.
- Risks Related to Our Reliance on Third Parties
- We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our vaccine candidates.
- We rely on third parties to supply raw materials and manufacture our preclinical and clinical product supplies of our vaccine candidates, and expect to rely on third parties to supply raw materials and produce and process our vaccine candidates, if approved. The loss of these suppliers or their failure to comply with applicable regulatory requirements or provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.
- If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.
- Risks Related to Government Regulation
- The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates.
- The FDA may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates.
- Even if we receive regulatory approval of our vaccine candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our vaccine candidates.
- We expect the vaccine candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
- Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, health information privacy and security laws and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.
- Coverage and reimbursement may be limited or unavailable in certain market segments for our vaccine candidates, which could make it difficult for us to sell our vaccine candidates, if approved, profitably.
- Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.
- The development, review and approval of our product candidates are subject to the operational capacity, processes and resource levels of regulatory authorities, which may fluctuate over time and could delay or adversely affect our business.
- Risks Related to Our Intellectual Property
- If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
- If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our vaccine candidates.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
- Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development, manufacturing and commercialization of our PCV candidates and any future vaccine candidate.
- We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.
- Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
- We may not be able to protect our intellectual property rights throughout the world, which could impair our business.
- Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.
- Risks Related to Ownership of Our Common Stock
- The price of our stock has been and may continue to be volatile, and the value of our common stock has and may continue to decline, any of which could result in substantial losses for investors.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- Expectations relating to environmental, social and governance programs may impose additional costs and expose us to new risks.
- Future sales of a substantial number of shares of our common stock, or the perception that such sales could occur, could cause our stock price to fall.
- Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
- Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- General Risk Factors
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or vaccine candidates.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
- Significant changes and volatility in trade policies could materially affect our business, financial condition, liquidity and results of operations, and stock price.
- Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.
- If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely consolidated financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.
- Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.
- Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
- If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
Legal proceedings
From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined unfavorably to us, would have a material adverse effect on our business, financial condition, operating results or cash flows. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve and divert management resources.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARVaxcyte, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARVaxcyte, Inc. filings on SEC EDGAR
- 4
- 5SEC EDGARVaxcyte, Inc. 10-K for fiscal 2019
- 6SEC EDGARVaxcyte, Inc. 10-K for fiscal 2020
- 7SEC EDGARVaxcyte, Inc. 10-K for fiscal 2021
- 8SEC EDGARVaxcyte, Inc. 10-K for fiscal 2022
- 9SEC EDGARVaxcyte, Inc. 10-K for fiscal 2023
- 10SEC EDGARVaxcyte, Inc. 10-Q for fiscal 2026
- 11SEC EDGARVaxcyte, Inc. 10-Q for fiscal 2026
- 12SEC EDGARVaxcyte, Inc. 10-K for fiscal 2019
- 13
- 14SEC EDGARAndrew Guggenhime, President
- 15
- 16SEC EDGARJim Wassil, Chief operating officer
- 17SEC EDGARLuis Jodar, Chief Medical Officer
- 18SEC EDGARElvia Cowan, Officer
- 19
- 20
- 21SEC EDGARJeff Fairman, VP, Research
- 22
- 23SEC EDGARJohn Markels, Board member
- 24SEC EDGARJacks Lee, Board member
- 25SEC EDGARTeri Loxam, Board member
- 26SEC EDGARAnne S. Drapeau, Board member
- 27SEC EDGARCarlos Paya V., Board member
- 28SEC EDGARMichael E. Kamarck, Board member
- 29SEC EDGARHalley E. Gilbert, Board member
- 30SEC EDGARHeath Lukatch, Board member
- 31SEC EDGARKurt Von Emster, Board member
- 32SEC EDGARMoncef Slaoui, Board member
- 33SEC EDGARPatrick J. Heron, Board member
- 34SEC EDGARPeter Hirth, Board member
- 35SEC EDGARRobert Lorne Hopfner, Board member
- 36SEC EDGARWilliam J. Newell, Board member
- 37
- 38
- 39
- 40
- 41SEC EDGARResults of operations
- 42SEC EDGARExecutive or director change
- 43SEC EDGARExecutive or director change
- 44SEC EDGARShareholder vote
- 45SEC EDGARResults of operations
- 46SEC EDGARResults of operations
- 47SEC EDGAROther events
- 48SEC EDGAROther events
- 49SEC EDGARExecutive or director change
- 50NasdaqNasdaq calendar
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68